MARKET

TECH

TECH

Bio-Techne Corp
NASDAQ
327.07
-3.33
-1.01%
After Hours: 334.99 +7.92 +2.42% 16:00 11/29 EST
OPEN
329.21
PREV CLOSE
330.40
HIGH
331.98
LOW
324.86
VOLUME
203.18K
TURNOVER
0
52 WEEK HIGH
522.96
52 WEEK LOW
271.73
MARKET CAP
12.84B
P/E (TTM)
45.82
1D
5D
1M
3M
1Y
5Y
Should You Invest in Bio-Techne Corporation (TECH)?
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, the fund posted a return of -4.87% gross of fees compared...
Insider Monkey · 1d ago
BIO-TECHNE TO PRESENT AT THE FIFTH ANNUAL EVERCORE ISI HealthCONx CONFERENCE
Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Fifth Annual Evercore ISI HealthCONx Conference on Tuesday, November 29, 2022, at 8:50 a.m. EST. A live webcast of the pres...
PR Newswire · 1d ago
Bio-Techne opens new immunoassay manufacturing facility
Seekingalpha · 11/15 13:01
BRIEF-Bio-Techne Announces Opening Of New Immunoassay Manufacturing Facility
Reuters · 11/15 12:07
BIO-TECHNE TO PRESENT AT THE STIFEL 2022 HEALTHCARE CONFERENCE
Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the Stifel 2022 Healthcare Conference on Tuesday, November 15, 2022, at 2:25 p.m. EST. A live webcast of the presen...
PR Newswire · 11/08 12:00
BIO-TECHNE TO PRESENT AT THE CREDIT SUISSE 31ST ANNUAL HEALTHCARE CONFERENCE
Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Credit Suisse 31st Annual Healthcare Conference on Wednesday, November 9, 2022, at 8:35 a.m. PST. A live webcast of the pre...
PR Newswire · 11/03 11:00
--SVB Securities Adjusts Price Target on Bio-Techne to $500 From $550, Maintains Outperform Rating
--SVB Securities Adjusts Price Target on Bio-Techne to $500 From $550, Maintains Outperform Rating
MT Newswires · 11/02 11:58
SVB Leerink Maintains Outperform on Bio-Techne, Lowers Price Target to $500
Benzinga · 11/02 08:42
More
About TECH
Bio-Techne Corporation is a developer, manufacturer, and seller of life science reagents, instruments and services for the research, diagnostics, and bioprocessing markets. The Company operates through two segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient options for automated western blot and multiplexed ELISA workflow. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits.

Webull offers kinds of BIO-TECHNE Corp stock information, including NASDAQ:TECH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TECH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TECH stock methods without spending real money on the virtual paper trading platform.